CiLostAzol for pReventIon of Recurrent sTroke in Africa
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 1,100
- 试验地点
- 1
- 主要终点
- Percent of Participants with Major Adverse Cardiovascular Events
研究概览
简要总结
Global estimates suggest that sub-Saharan Africa (SSA) now has the highest incidence, prevalence, and worst survival outcomes of stroke. With an estimated 1.4 million stroke survivors, outcomes of stroke in SSA are abysmal with 1-month case fatality at 30% and 3-year mortality rate of 84%. Stroke survivors in Africa are at an inordinately high (and worsening) risk of adverse outcomes including recurrent stroke and cardiac events over the medium- to longterm. Given the paucity of resources in the region, testing of therapies, which are potentially highly clinically efficacious and cost-effective, while developing local stroke research capacity and contributing to the global secondary stroke prevention evidence base, is urgently needed. Cilostazol, a phosphodiesterase 3 inhibitor, has shown promising efficacy and safety mainly among an Asian population by cutting risk of major adverse cardiovascular events including stroke, in half, when added to aspirin or clopidogrel (8% vs. 4%, HR 0.52, 95% CI 0.35-0.77), with no increased risk in bleeding or serious adverse events. Cilostazol's potentially strong efficacy, presumed pleiotropic effects, and relatively low cost, make it a highly appealing agent for use in stroke-prone, low-resource settings. Therefore, the overall objective of the CiLostAzol for pReventIon of recurrent sTroke in Africa (CLARITY-AFRICA) study is to deploy a hybrid study design to demonstrate the efficacy and safety of cilostazol twice daily in reducing MACE over 24 months vs. placebo among 1100 recent stroke patients encountered at 12 hospitals in Ghana. Secondly, CLARITY-AFRICA also seeks to develop an implementation strategy for routine integration and policy adoption of cilostazol for post-stroke cardiovascular risk reduction in an under-resourced system. Given its compelling efficacy among a predominantly Asian population, the National Institute of Neurological Disorders and Stroke (NINDS) is poised to fund a US-based clinical trial to assess the longer-term efficacy and safety of cilostazol in a study titled CiLostAzol for pReventIon of recurrent sTroke (CLARITY). The investigators are also aware that European and Australian funding agencies are considering stroke trials of cilostazol. A concurrently executed CLARITYAfrica trial would allow recruitment of a historically underrepresented and high-risk group (Africans), test a therapy that if efficacious could be affordable for broader regional implementation, permit transcontinental mentorship/collaborations, and leverage NINDS impending investment. CLARITY-AFRICA will assess implementation outcomes such as adoption, acceptability, cost, pertinent to uptake of cilostazol in Ghana to inform policy. Regardless of its outcome, findings from CLARITYAFRICA will contribute meaningful information from the African perspective to inform the formulation of guidelines for global adoption of cilostazol into routine care for secondary CVD risk prevention by international bodies such as the World Health Organization. This application will focus on the first 2 aims of CLARITY-AFRICA to conduct the trial and assess secondary outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Above the age of 30 years; male or female (sex is a biological variable of interest)
- •Ischemic stroke or high-risk TIA (ABCD2 score >= 6) diagnosis no greater than six months before enrollment. Ischemic strokes including lacunar, large vessel atherosclerotic, embolic stroke of undetermined source subtypes are eligible (Ischemic stroke or TIA should be confirmed by either with a cranial CT or MRI within 10 days of symptom onset)
- •Aspirin or clopidogrel monotherapy
- •Subjects with stroke may present with two or more of the following additional conditions: age ≥65 years, documented diabetes mellitus or previous treatment with oral hypoglycemic or insulin; documented hypertension >140/90mmHg or previous treatment with anti-hypertensive medications; Mild to moderate renal dysfunction (eGFR 60-30ml/min/1.73m2); Prior myocardial infarction
- •Legally competent to sign informed consent or have a LARs who is able to provide consent for them
- •In the opinion of the treating physician, patient is medically stable, capable of participating in a randomized trial, and willing and able to attend follow-up.
- •Able to do labs at all study intervals (7 visits total)
排除标准
- •Unable to provide a valid informed consent
- •Contraindications to cilostazol (namely (i) hypersensitivity, (ii) active pathologic bleeding, e.g. bleeding peptic ulcer, intracranial bleeding due to reversible platelet aggregation, (iii) congestive cardiac failure.)
- •Hemorrhagic stroke survivor within the last 2 years
- •Use of an anticoagulant medication or indication for use of an anticoagulant (e.g. atrial fibrillation)
- •On dual antiplatelet therapy (patients are eligible after completion of a course of dual antiplatelet therapy)
- •Modified Rankin Scale 5
- •Thrombocytopenia (platelet count <1000,000)
- •Severe liver dysfunction (active hepatitis or hepatic insufficiency with Child-Pugh score B or C)
- •Congestive heart failure, defined as NYHA Class III or above (marked limitation of physical activity)
- •Nursing/pregnant mothers
研究组 & 干预措施
Cilostazol Experimental Arm
Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study.
干预措施: Cilostazol 100 mg (Drug)
Control Arm
Standard of post-stroke care
结局指标
主要结局
Percent of Participants with Major Adverse Cardiovascular Events
时间窗: 36 months
次要结局
- Percent of Participants with of Major and Minor bleeding(24 months)
- Percent of Participants with Recurrent stroke (Ischemic or Hemorrhagic)(24 months)
- Percent of Participants with Cardiovascular Deaths(24 months)
- Percent of Participants with All Cause Mortality(24 months)
- Neuro-QoL (Quality of Life)(24 months)
- Exploratory outcomes Montreal Cognitive Assessment(24 months)
- Quality of Life (EQ-5D Questionnaire)(24 months)
- Modified Rankin Score(24 months)
- Percent of Participants with of Major and Minor bleeding(24 months)
- Percent of Participants with Cardiovascular Deaths(24 months)
- Percent of Participants with Recurrent stroke (Ischemic or Hemorrhagic)(24 months)
- Percent of Participants with All Cause Mortality(24 months)
- Neuro-QoL (Quality of Life)(24 months)
- Exploratory outcomes Montreal Cognitive Assessment(24 months)
- Quality of Life (EQ-5D Questionnaire)(24 months)
- Modified Rankin Score(24 months)
研究者
Bruce Ovbiagele
Chief of Staff
Northern California Institute of Research and Education